Browsing by Author "Brock, Jane"

Now showing items 1-4 of 4

    • Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients 

      Phillips, Kathryn A.; Marshall, Deborah A.; Haas, Jennifer S.; Elkin, Elena B.; Liang, Su-Ying; Hassett, Michael James; Ferrusi, Ilia; Brock, Jane Elizabeth; Van Bebber, Stephanie L. (Wiley-Blackwell, 2009)
      BACKGROUND: Testing technologies are increasingly used to target cancer therapies. Human epidermal growth factor receptor 2 (HER2) testing to target trastuzumab for patients with breast cancer provides insights into the ...

    • Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry 

      Kluk, Michael J.; Ashworth, Todd; Wang, Hongfang; Knoechel, Birgit; Mason, Emily F.; Morgan, Elizabeth A.; Dorfman, David; Pinkus, Geraldine; Weigert, Oliver; Hornick, Jason L.; Chirieac, Lucian R.; Hirsch, Michelle; Oh, David J.; South, Andrew P.; Leigh, Irene M.; Pourreyron, Celine; Cassidy, Andrew J.; DeAngelo, Daniel J.; Weinstock, David M.; Krop, Ian E.; Dillon, Deborah; Brock, Jane E.; Lazar, Alexander J. F.; Peto, Myron; Cho, Raymond J.; Stoeck, Alexander; Haines, Brian B.; Sathayanrayanan, Sriram; Rodig, Scott; Aster, Jon C. (Public Library of Science, 2013)
      Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been ...

    • Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer 

      Tolaney, Sara M.; Tan, Sally; Guo, Hao; Barry, William; Van Allen, Eliezer; Wagle, Nikhil; Brock, Jane; Larrabee, Katherine; Paweletz, Cloud; Ivanova, Elena; Janne, Pasi; Overmoyer, Beth; Wright, John J.; Shapiro, Geoffrey I.; Winer, Eric P.; Krop, Ian E. (Springer US, 2015)
      Summary Background: MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although ...

    • Prevalence and Predictors of Loss of Wild Type BRCA1 in Estrogen Receptor Positive and Negative BRCA1-Associated Breast Cancers 

      Fetten, Katharina; Yassin, Yosuf; Buraimoh, Ayodele; Kim, Ji-Young; Legare, Robert D; Tung, Nadine Muskatel; Miron, Alexander; Schnitt, Stuart Jay; Gautam, Shiva Prasad; Kaplan, Jennifer; Szasz, Attila M.; Tian, Ruiyang; Wang, Zhigang C.; Collins, Laura Christine; Brock, Jane Elizabeth; Krag, Karen; Sgroi, Dennis Charles; Ryan, Paula D.; Silver, Daniel P.; Garber, Judy Ellen; Richardson, Andrea Lynn (BioMed Central, 2010)
      Introduction: The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers ...